Capivasertib - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for capivasertib and what is the scope of freedom to operate?
Capivasertib
is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Capivasertib has eighty-seven patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for capivasertib
| International Patents: | 87 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 23 |
| What excipients (inactive ingredients) are in capivasertib? | capivasertib excipients list |
| DailyMed Link: | capivasertib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capivasertib
Generic Entry Date for capivasertib*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for capivasertib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Taiwan University Hospital | Phase 2 |
| VA Office of Research and Development | Phase 2 |
| Quotient Sciences | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for capivasertib
US Patents and Regulatory Information for capivasertib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for capivasertib
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 2272517 | ⤷ Try a Trial | |
| Canada | 2701057 | DERIVES PYRROLO[2,3-D]PYRIMIDINE COMME INHIBITEURS DE LA PROTEINE KINASE B (PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS) | ⤷ Try a Trial |
| Spain | 2368493 | ⤷ Try a Trial | |
| Japan | 2011500547 | ⤷ Try a Trial | |
| Denmark | 2201012 | ⤷ Try a Trial | |
| South Africa | 201002318 | PYRROLO [2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
